A Biliary Stricture After Transplant: Bridging With UDCA While Waiting for the Stent
A rising cholestatic picture from a mechanical anastomotic stricture, a three-week wait for the ERCP slot that actually fixes it, and whether starting a bridge therapy risks the fix being forgotten.
Carol S., 49, has taught second grade for over twenty years and returned to her classroom within four months of her liver transplant three years ago — a fact she brings up, unprompted, whenever the team asks how she's doing. Transplanted for cirrhosis from autoimmune hepatitis, she's been on a stable maintenance regimen of tacrolimus and low-dose mycophenolate since, with no rejection episodes in the interim, and routine post-transplant labs the only thing that's changed recently: her alkaline phosphatase and GGT have been climbing steadily over the past six weeks. MRCP found the reason — a focal stricture at the biliary anastomosis, with mild dilation of the ducts upstream of it. A protocol liver biopsy done around the same time showed no evidence of rejection, which leaves obstruction as the only explanation left standing for the enzyme rise. Her bilirubin is the number that sets the clock: still normal, six weeks into a climbing alkaline phosphatase and GGT. A stricture tight enough to lift the canalicular enzymes but not yet tight enough to back up conjugated bilirubin is one that can be watched for three weeks; the day the bilirubin moves, the wait stops being defensible. ERCP with stenting has already been arranged to correct the stricture directly, but the advanced endoscopy service at her transplant center has a three-week wait before a slot opens.
Ursodeoxycholic acid reliably lowers alkaline phosphatase and GGT across cholestatic liver disease generally, and that is the whole of what can honestly be claimed for it here: there is no trial of UDCA in anastomotic biliary strictures, and a biomarker is not an outcome. The cautionary precedent sits close by — in primary sclerosing cholangitis, Lindor's high-dose trial improved liver chemistries while the patients taking it did worse, which is the clearest available demonstration that in a cholestatic liver those two things can move in opposite directions. What it can't do is open a narrowed anastomosis; only the stent does that. The real risk isn't pharmacologic, it's procedural in a different sense — that improving alkaline phosphatase and GGT numbers on UDCA get read, by someone down the line who wasn't in today's conversation, as evidence the problem has resolved, and the ERCP slot quietly loses its urgency. Both the medication and the mechanical fix are needed here; the open question is how to make sure starting one doesn't accidentally undercut everyone's memory that the other is still required — a real risk given how many different covering physicians a stable, years-out transplant patient like Carol tends to see between one scheduled visit and the next.
In transplant clinic, with the ERCP slot three weeks out
Her cholestatic markers are rising and she has three weeks before the stent slot opens. UDCA lowers cholestatic markers dependably across cholestatic disease, it's well tolerated at standard dose, and three weeks of reduced cholestatic load is a reasonable thing to want for a graft. He'll say plainly what he isn't claiming: there's no anastomotic-stricture trial behind this, and Lindor's PSC experience stands as a reminder that better chemistries aren't automatically a better liver.
The stricture is mechanical. UDCA doesn't open a narrowed anastomosis — only the stent does that. Worried that if her alkaline phosphatase and GGT come down on UDCA, someone down the line — maybe not in this room, maybe a covering physician weeks from now — reads that improvement as the problem resolving and lets the ERCP slip. Lindor's patients had better numbers too.
"Gives the graft protection during the wait" is true, but it says nothing about making sure the wait actually ends on schedule, which is the part that actually protects her long-term.
Those aren't actually competing plans. Start the UDCA — it's real bridge therapy with genuine benefit during a wait that's happening regardless — and write into today's note, explicitly, that UDCA is bridge therapy only, the anastomotic stricture requires endoscopic correction regardless of biomarker trend, and the ERCP slot is not to be deferred based on lab improvement. That documentation is what actually prevents the failure mode being described — not withholding a low-risk medication that's helping her graft in the meantime.
Agreed to start UDCA today with the explicit bridge-therapy documentation the pharmacologist proposed written directly into her chart and communicated to the covering transplant team, and the endoscopist confirmed the ERCP slot rather than leaving it to stand as a routine referral.
Not agreed: whether to also call the advanced endoscopy scheduler directly today to ask about an earlier cancellation slot, which the hepatologist wanted to try given how close her rising markers already are to previous flare thresholds; the transplant surgeon thought three weeks was an acceptable, medically reasonable wait and didn't want to push an already-full advanced endoscopy schedule for a patient who isn't in immediate danger.